Sarclisa Specified Drug Use Investigation (Monotherapy / with Dexamethasone / with Carfilzomib and Dexamethasone) (Relapsed or refractory multiple myeloma)

Sarclisa Specified Drug Use Investigation (Monotherapy / with Dexamethasone / with Carfilzomib and Dexamethasone) (Relapsed or refractory multiple myeloma) - Sarclisa Specified Drug Use Investigation (Monotherapy / with Dexamethasone / with Carfilzomib and Dexamethasone) (Relapsed or refractory multiple myeloma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047806

Enrollment

Registered

2022-05-26

Start date

2022-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will receive Sarclisa (Monotherapy / with Dexamethasone / with Carfilzomib and Dexamethasone).

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Drug Reaction)	—

Secondary

Measure	Time frame
Effectiveness	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance -

Sanofi K.K. Post-authorization regulatory studies, Medical Affairs

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results